NAGE
Niagen Bioscience Inc
$
9.770
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
10.060
Open
10.060
VWAP
9.90
Vol
501.90K
Mkt Cap
807.10M
Low
9.650
Amount
4.97M
EV/EBITDA(TTM)
42.79
Total Shares
79.75M
EV
746.78M
EV/OCF(TTM)
35.21
P/S(TTM)
7.16
Niagen Bioscience, Inc., formerly Chromadex Corp., is a global bioscience company. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. The Company’s Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers and distributors and offers NAD+ test kits exclusively to healthcare practitioners. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and United States FDA-registered 503B outsourcing facilities, respectively. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
Show More
4 Analyst Rating
54.86% Upside
Wall Street analysts forecast NAGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAGE is 15.13 USD with a low forecast of 10.50 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
54.86% Upside
Current: 9.770
Low
10.50
Averages
15.13
High
23.00
54.86% Upside
Current: 9.770
Low
10.50
Averages
15.13
High
23.00
H.C. Wainwright
Buy
maintain
$11 -> $12
2025-08-11
New
Reason
H.C. Wainwright
Price Target
$11 -> $12
2025-08-11
New
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Niagen Bioscience to $12 from $11 and keeps a Buy rating on the shares. The company's Q2 revenue and earnings beat expectations, the analyst tells investors in a research note.
Canaccord
Buy
maintain
$13 -> $16
2025-06-10
Reason
Canaccord
Price Target
$13 -> $16
2025-06-10
maintain
Buy
Reason
Canaccord raised the firm's price target on Niagen Bioscience to $16 from $13 and keeps a Buy rating on the shares. Niagen Bioscience announced positive clinical study results that were recently published in the peer-reviewed journal Aging Cell, with the study centered around the safety of NAD+ supplementation on those with Werner syndrome, with secondary endpoints focused on NAD+ levels in patients with WS and other impacts on patients, including liver, kidney, and arterial health, the analyst tells investors in a research note. The published double-blind and placebo-controlled study highlighted the safety of NAD+ supplementation on patients with WS and also helped significantly increase NAD+ levels in blood by ~140%, along with improving various clinical markers for those with WS, the firm says, adding that this is a "positive first step."
Roth Capital
Buy
maintain
$10 -> $23
2025-06-06
Reason
Roth Capital
Price Target
$10 -> $23
2025-06-06
maintain
Buy
Reason
Roth Capital raised the firm's price target on Niagen Bioscience to $23 from $10 and keeps a Buy rating on the shares. The stock has been "very strong" over the last year and continues to offer significant upside potential from the expansion of its addressable markets pending the outcome of a number of trials and studies currently in process, the analyst tells investors in a research note. Roth further cites the continued strong growth in sales of TruNiagen, the company's core product, its immunity from the impact of tariffs, and encouraging progress being made in several new initiatives, include Niagen Plus, which began rolling out to clinics in late 2024.
Canaccord
Susan Anderson
Buy
initiated
$13
2025-05-27
Reason
Canaccord
Susan Anderson
Price Target
$13
2025-05-27
initiated
Buy
Reason
Canaccord analyst Susan Anderson initiated coverage of Niagen Bioscience with a Buy rating and $13 price target.
Canaccord
Susan Anderson
Buy
initiated
$13
2025-05-27
Reason
Canaccord
Susan Anderson
Price Target
$13
2025-05-27
initiated
Buy
Reason
Canaccord analyst Susan Anderson initiated coverage of Niagen Bioscience with a Buy rating and $13 price target. Niagen, formerly known as ChromaDex, has evolved into a bioscience company centered around researching and commercializing nicotinamide adenine dinucleotide and other precursors to help with healthy aging, the analyst tells investors in a research note. The firm says that various studies have indicated that a decline in NAD+ levels leads to age-related disease and health conditions. This is where Niagen comes in as it offers products to help boost NAD+ levels, notes Canaccord. It believes Niagen offers a "unique opportunity to invest into a fast-growing consumer health care company with further growth upside."
See All Ratings
Valuation Metrics
The current forward P/E ratio for Niagen Bioscience Inc (NAGE.O) is 68.40, compared to its 5-year average forward P/E of 79.73. For a more detailed relative valuation and DCF analysis to assess Niagen Bioscience Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
79.73
Current PE
68.40
Overvalued PE
103.11
Undervalued PE
56.35
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
49.57
Current EV/EBITDA
39.86
Overvalued EV/EBITDA
60.39
Undervalued EV/EBITDA
38.75
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
5.80
Current PS
5.93
Overvalued PS
7.06
Undervalued PS
4.54
Financials
Annual
Quarterly
FY2025Q2
YoY :
+36.84%
31.12M
Total Revenue
FY2025Q2
YoY :
-1344.14%
3.19M
Operating Profit
FY2025Q2
YoY :
-24160.00%
3.61M
Net Income after Tax
FY2025Q2
0.04
EPS - Diluted
FY2025Q2
YoY :
-503.99%
1.12M
Free Cash Flow
FY2025Q2
YoY :
+7.94%
65.00
Gross Profit Margin - %
FY2025Q2
YoY :
+1478.95%
18.00
FCF Margin - %
FY2025Q2
YoY :
-16671.43%
11.60
Net Margin - %
FY2025Q2
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
NAGE News & Events
Events Timeline
2025-07-08 (ET)
2025-07-08
09:19:33
Niagen Bioscience licenses potential Parkinson's therapy
2025-06-09 (ET)
2025-06-09
09:07:30
Niagen Bioscience presents results in journal Aging Cell
2025-05-07 (ET)
2025-05-07
16:39:48
Niagen Bioscience sees FY25 revenue up 20%-25%, consensus $118.5M
Sign Up For More Events
Sign Up For More Events
News
4.0
08-11BenzingaHC Wainwright & Co. Maintains Buy on Niagen Bioscience, Raises Price Target to $12
9.5
08-06NASDAQ.COMNiagen NAGE Q2 2025 Earnings Call Transcript
1.0
08-04NewsfilterNiagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference
Sign Up For More News
People Also Watch
META
Meta Platforms Inc
782.710
USD
+0.34%
AAPL
Apple Inc
232.880
USD
-0.19%
NVDA
NVIDIA Corp
182.020
USD
+0.24%
AMZN
Amazon.com Inc
231.310
USD
+3.01%
AVGO
Broadcom Inc
311.460
USD
+0.77%
WMT
Walmart Inc
100.895
USD
-0.09%
TSLA
Tesla Inc
334.620
USD
-1.40%
MSFT
Microsoft Corp
521.860
USD
+0.25%
ORCL
Oracle Corp
244.350
USD
+0.07%
XOM
Exxon Mobil Corp
107.290
USD
-0.29%
FAQ
What is Niagen Bioscience Inc (NAGE) stock price today?
The current price of NAGE is 9.77 USD — it has decreased -3.46 % in the last trading day.
What is Niagen Bioscience Inc (NAGE)'s business?
What is the price predicton of NAGE Stock?
What is Niagen Bioscience Inc (NAGE)'s revenue for the last quarter?
What is Niagen Bioscience Inc (NAGE)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Niagen Bioscience Inc (NAGE)'s fundamentals?
How many employees does Niagen Bioscience Inc (NAGE). have?